Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma.
about
E-cadherin's dark side: possible role in tumor progressionEvaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinomaDevelopment of flexible-heteroarotinoids for kidney cancerDisseminated breast cancer cells acquire a highly malignant and aggressive metastatic phenotype during metastatic latency in the bone.The VHL tumor suppressor and HIF: insights from genetic studies in miceExon 11 skipping of E-cadherin RNA downregulates its expression in head and neck cancer cellsMicroRNA-720 regulates E-cadherin-αE-catenin complex and promotes renal cell carcinoma.Feline sarcoma-related protein expression correlates with malignant aggressiveness and poor prognosis in renal cell carcinoma.Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell CarcinomaAltered expression of β-catenin, E-cadherin, and E-cadherin promoter methylation in epithelial ovarian carcinoma.Surgical treatment of renal cell carcinoma: Can morphological features of inferior vena cava tumor thrombus on computed tomography or magnetic resonance imaging be a prognostic factor?EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins.Nuclear E-cadherin Expression is Associated with the Loss of Membranous E-cadherin, Plasmacytoid Differentiation and Reduced Overall Survival in Urothelial Carcinoma of the Bladder
P2860
Q26865483-9BC7B459-51FB-4420-8E11-B386283A9CC8Q33723974-9CB96682-136E-488F-BB00-13A622654B32Q33926659-20569BE8-FDEF-4BE6-AC86-AC8838A5299CQ34485079-985A4256-1A53-4296-BC53-2E07AFD117C6Q37064867-5DDE2B0B-CBE9-4D34-B0E3-6C10994EDFC1Q38366355-64938B60-A26E-4804-8124-18F19EDA58A4Q38695055-41DC1C48-F92B-4AB1-A7A1-47EA8CC4B225Q39187777-71FB979C-AE69-4BDB-AC23-54E96F84EA59Q39773550-D750F845-308E-4227-B8A3-CE174AB87FD0Q41919666-2D33B833-C8FB-4F45-BAEE-EB63134F5C13Q44387949-6C75F68A-3CB3-4A39-8BDB-91CA5DCC01D5Q52922320-4037FA9B-5C83-42F2-98B4-463FD4463A6AQ53247248-9EF6BB70-1257-486D-B44F-AC715DF2005CQ56565910-ADB6A909-2F75-47B7-B2D2-3E0568129B18
P2860
Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Nuclear E-cadherin and VHL imm ...... ear-cell renal cell carcinoma.
@en
type
label
Nuclear E-cadherin and VHL imm ...... ear-cell renal cell carcinoma.
@en
prefLabel
Nuclear E-cadherin and VHL imm ...... ear-cell renal cell carcinoma.
@en
P2093
P2860
P1476
Nuclear E-cadherin and VHL imm ...... ear-cell renal cell carcinoma.
@en
P2093
Andrew J Evans
Arthy Saravanan
Michael A S Jewett
Michael Ohh
Michelle L Gervais
Pauline C Henry
Richard P Hill
T Nadine Burry
P2860
P2888
P304
P356
10.1038/LABINVEST.3700684
P577
2007-10-01T00:00:00Z
P6179
1008963317